health · family: designed for a world that doesn’t exist here
invisible tothe system
Cervical cancer screening coverage is low across low- and middle-income countries because screening was designed around the clinician, not the woman
Problem statement
Cervical cancer is the fourth most common cancer in women worldwide, killing over 348,000 women in 2022 — nearly 90% of them in low- and middle-income countries. The cancer is preventable through screening and treatable when caught early, yet screening coverage in low- and middle-income countries is generally low: in Demographic and Health Surveys from 16 countries between 2010 and 2019, the share of women who had been screened ranged from 0.7% in Benin to 93.3% in Colombia. The WHO 90-70-90 elimination strategy requires 70% screening coverage by 2030, and that study concluded that coverage in low- and middle-income countries was low. The fundamental problem is not the absence of screening technology — it's that the screening model was designed around the provider (requiring clinic visits, trained clinicians, speculum exams, and laboratory infrastructure) rather than around the woman who needs to be screened.
Why this matters
WHO's Global Strategy defines cervical cancer elimination as fewer than 4 cases per 100,000 women per year. The inequity is stark: higher screening rates have been reported from high-income countries — a Canadian study reported 72%, against 11% in Kenya, 66% in Jamaica, 4.8% in Uganda and 22.9% in Nigeria in studies from low- and middle-income countries — and in low- and middle-income countries cervical cancer incidence is nearly twice as high and mortality three times as high as in high-income countries. A systematic review covering 202 countries and territories estimated global screening coverage at 36% ever in a lifetime and 32% in the past five years. The disease burden falls disproportionately on women who are poor, rural, uninsured, and from marginalized communities — the same women for whom clinic-based screening is least accessible. Most low- and middle-income countries have not established national cervical cancer screening services.
What’s been tried and why it hasn’t worked
Clinic-based screening programs using Pap smears or visual inspection with acetic acid (VIA) have been the standard approach for decades. These require trained providers, laboratory infrastructure, and multiple clinic visits — women must attend for sampling, return for results, and return again for treatment if positive. Each step loses patients: where a positive HPV result requires an additional visit for cytology, 35–45% of patients drop out during follow-up. The provider-collected sample requirement is the primary structural barrier: it requires women to travel to a facility, take time away from work and family responsibilities, undergo a pelvic examination (a source of embarrassment, including being examined by a male or young health worker), and return repeatedly. A systematic review of 79 studies from 28 LMICs found lack of knowledge and awareness of cervical cancer and of screening to be the most frequent individual-level barriers, alongside cultural and religious prohibitions, lack of partner approval or support, fear of pain from the procedure or of a positive result, and structural barriers of distance, travel cost, and screening cost where screening is not free. Over 250 HPV tests are commercially available, but few are validated, affordable, and suitable for point-of-care use in low-resource settings. The research base itself reflects the inequity: a scoping review of 124 self-sampling studies in LMICs found that most mentioned equity factors such as age, education and place of residence, but none analysed their impact.
What would unlock progress
HPV self-sampling — where women collect their own vaginal sample at home or in a community setting — eliminates the need for clinic attendance, trained providers, and speculum exams. Meta-analyses show it can increase screening participation by 1.5 to 2.5 times compared with traditional methods, in resource-limited settings it reduces costs by 32–48%, and it reaches women who have never been screened. Vaginal brushes achieve 94.6% sensitivity for HPV detection. However, self-sampling only solves half the problem. What's still needed is: (1) a low-cost, accurate, point-of-care HPV test that can process self-collected samples without laboratory infrastructure — isothermal amplification and lateral flow detection enable low-cost, sample-to-answer HPV testing suitable for decentralised screening, but validated, affordable, high-performance HPV tests remain in limited supply; (2) a "screen-and-treat" workflow where a positive result leads to immediate treatment in the same visit, eliminating the dropout between screening and treatment; and (3) integration with existing community health systems (community health workers, mobile health platforms) so that screening reaches women rather than waiting for women to reach screening.
Entry points for student teams
A student team could design a community-based cervical cancer screening workflow that integrates self-sampling with a low-cost point-of-care HPV test and a decision-support tool for community health workers. The deliverable would be a service design prototype (workflow, logistics, communication materials, data tracking) tested with a specific population segment — for example, women in a peri-urban community who have never been screened. A more technically oriented team could work on the sample-to-answer challenge: designing a low-cost sample processing method that bridges the gap between self-collected samples and affordable HPV detection, potentially using paper-based microfluidics or isothermal amplification. Skills in public health, service design, biomedical engineering, or behavioral science would be most relevant.
Genes
Structural cousins: stuck the same way, in other fields
Sources
WHO, "Target product profiles for human papillomavirus screening tests to detect cervical pre-cancer and cancer," 2024, (accessed 2026-02-14). Supplemented with: "Advancing Cervical Cancer Prevention Equity: Innovations in Self-Sampling and Digital Health Technologies Across Healthcare Settings," Diagnostics 15(9):1176, 2025, "Human papillomavirus self-sampling versus provider-sampling in low- and middle-income countries: a scoping review of accuracy, acceptability, cost, uptake, and equity," Frontiers in Public Health, 2024, "Coverage and Socioeconomic Inequalities in Cervical Cancer Screening in Low- and Middle-Income Countries Between 2010 and 2019," JCO Global Oncology, 2024, "Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: a systematic review," BMC Women's Health, 2022, go to source 1 ↗ go to source 2 ↗ go to source 3 ↗ go to source 4 ↗ go to source 5 ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
- This brief is a strong example of `failure:wrong-stakeholder`: the entire screening system was designed around the provider as the key actor (who collects the sample, reads the result, provides treatment), when the woman herself should be the central actor. Self-sampling reframes the stakeholder — but the downstream steps (testing, treatment) still require provider infrastructure, creating a partial solution.
- The barriers review finds lack of knowledge and awareness to be the most frequent individual-level barrier, but also reports poor uptake among well-informed women who face religious, cultural, health-system and structural barriers; awareness and access are both bottlenecks, and the case for self-sampling rests on the access side (embarrassment at the pelvic exam, distance, travel and screening cost, competing demands on time).
- The scoping review's finding that none of 124 LMIC self-sampling studies analysed the impact of equity factors is itself a manifestation of `failure:unrepresentative-data` — the evidence base for self-sampling does not yet show who within these populations it reaches.
- Cross-domain connection: the dropout between screening and treatment mirrors the "diagnosis-to-treatment gap" seen in many health system challenges. The structural pattern is identical to the cold chain "first mile" problem in `agriculture-smallholder-cold-chain-access` — the hardest segment to serve is the most distributed and heterogeneous.
- WHO's 2024 TPP development for HPV tests explicitly names access, equity and affordability as integral parts of the innovation process, to be considered from the early research and development stages.
Reconciliation 2026-09-30: Round 6 read of the whole write-up against all five named sources, fetched 2026-09-30. The WHO target product profiles (2024) were read in full as the PDF served by WHO's IRIS repository (item 10665/379099, bitstream 544db89c-fb23-49e7-b27d-6ee0e625fb05), after the who.int page gave only the summary. The Diagnostics review (Gomes et al. 2025) and the BMC Women's Health review (Petersen et al. 2022) were read in full from Europe PMC (PMC12071443 and PMC9716693), since mdpi.com and springer.com block scripts. The Frontiers scoping review (2024) was read in full from the journal page. The JCO Global Oncology study (Abila et al. 2024) was read in full, including its tables, from the Internet Archive copy of the ascopubs.org page, since ascopubs.org itself returned a robot check. Changes: (1) The long title and the Problem Statement said 90% of women in low-income countries have never been screened. No source gives that figure. The JCO study reports that coverage in surveys from 16 low- and middle-income countries between 2010 and 2019 ranged from 0.7% in Benin to 93.3% in Colombia and was "generally low"; the title now says coverage is low across low- and middle-income countries, and the Problem Statement gives the JCO range. Old title: "90% of Women in Low-Income Countries Have Never Been Screened for Cervical Cancer Because Screening Was Designed Around the Clinician, Not the Woman". New title: "Cervical Cancer Screening Coverage Is Low Across Low- and Middle-Income Countries Because Screening Was Designed Around the Clinician, Not the Woman". (2) "Current coverage in low-income countries is under 10%" is in no source; the sentence now gives the JCO study's own conclusion that coverage in low- and middle-income countries was low. (3) "At current trajectories, most low-income countries will not achieve this within the century" is in no source and was removed. (4) "Screening coverage is 7 times higher in high-income than in low-income countries" is in no source; the sentence now gives the JCO study's own comparison (72% in a Canadian study against 11% in Kenya, 66% in Jamaica, 4.8% in Uganda and 22.9% in Nigeria in studies from low- and middle-income countries) and the WHO document's statement that incidence in low- and middle-income countries is nearly twice, and mortality three times, that of high-income countries. (5) "1.6 billion women aged 20–70 globally have never been screened, including 804 million in lower-middle-income countries and 152 million in low-income countries" is in no source and was replaced by the global estimate the JCO study cites (36% ever screened, 32% in the past five years, across 202 countries and territories). (6) "61% of low-income countries still lack official screening recommendations" is in no source (the only 61% in the sources is the share of the BMC review's studies done in Africa); the sentence now follows the JCO study, which says most low- and middle-income countries have not established national screening services. (7) "Studies in LMICs show 30–50% dropout between screening and treatment" is in no source; the Diagnostics review reports 35–45% dropout during follow-up where a positive HPV result requires an additional cytology visit, and the sentence now says that. (8) "Wage loss that the poorest cannot afford", "examination by a stranger", "modesty norms" and "lack of childcare" are not in the BMC review, which reports competing demands on time from work and family, embarrassment at the pelvic examination including being examined by a male or young health worker, prohibition of screening, lack of partner approval or support, fear of pain and of a positive result, distance, travel cost and screening cost; the passage now follows the review. (9) The sentence "In one study, 90% of women knew that early detection could prevent cervical cancer but only 9% had been screened — demonstrating that the problem is access, not awareness" is in no source, and the BMC review says the opposite: lack of knowledge and awareness was the most frequent individual-level barrier. The sentence was replaced with the review's findings, and the Source Notes bullet built on it was rewritten to carry both the review's headline finding and its report of poor uptake among well-informed women. (10) "Only 3 of 72 studies in a major systematic review of self-sampling preferences were conducted in low-income countries" is in no source; the Frontiers scoping review included 124 studies and reports that most mentioned equity factors but none analysed their impact, which the text and the related Source Notes bullet now say. (11) "Increases screening participation by 32–48%" misread the Diagnostics review, where 32–48% is the cost reduction from self-sampling; the participation figure there is an increase of 1.5 to 2.5 times, and the sentence now gives both, with the cost figure tied to resource-limited settings as the review states it. (12) "Isothermal amplification and lateral flow approaches are promising but not yet at the price and performance point needed" is not what the sources say; the Diagnostics review says these enable low-cost, sample-to-answer testing for decentralised screening, and WHO says validated, affordable, high-performance tests are in limited supply; the sentence now follows them. (13) The Source Notes bullet said the 2024 TPP represents "a shift from earlier TPPs that focused primarily on technical performance"; the WHO document says only that the first HPV TPP was part of the 2014 STI point-of-care TPPs, so the bullet now states what the document says about access, equity and affordability. (14) The Frontiers citation on the Source line carried a shortened title; it now carries the full title from the journal page. Confirmed against the sources and left as written: fourth most common cancer in women (WHO, BMC, JCO); over 348,000 deaths in 2022 (JCO 348,186; WHO around 349,000); about 90% of deaths in low- and middle-income countries (Diagnostics, BMC); the 90-70-90 targets and 70% screening by 2030 (WHO, Diagnostics); elimination below 4 per 100,000 women (Diagnostics, JCO); lower coverage among poor, rural and less-educated women (JCO); more than 250 commercial HPV tests with limited availability of validated, affordable point-of-care tests (WHO); 94.6% sensitivity for vaginal brushes (Diagnostics); screen-and-treat and same-visit treatment reducing loss to follow-up (WHO); the citation details for the other four sources. Not checked: the framing that screening was "designed around the clinician" is the write-up's own diagnosis, not a statement made by any source, and is left as the brief's thesis. A second reader went over all fourteen repairs the same day against independently fetched copies of the five sources; all stand, with the wording of (2), (4), (8), (9) and (11) tightened so that each says no more than its source. Genome tags untouched.